



RESEARCH TOPIC CLI13

Inflammatory predictors of progression to end-stage heart failure

Clinical Unit name

Cardiovascular Department
IRCCS – Humanitas Research Hospital

Supervisor

Gianluigi Condorelli
gianluigi.condorelli@hunimed.eu

Abstract

Although initially debated, the role of inflammation in the development and progression of heart failure is now clearer. Despite new evidence, it has still not been demonstrated any beneficial effect in the use of immunomodulatory drugs with regard to the progression of the disease itself, particularly in the most advanced stages. The main objective of the proposed project is to immunologically characterize the inflammatory substrate of patients with stage C heart failure and to evaluate predictors of progression to an advanced stage of heart failure (D). This project will use experimental analyses (FACS, mass cytometry, single-cell RNA sequencing) upon inclusion and during patient follow-up, with the aim of identifying subpopulations that may in the future benefit from additional therapies to mitigate the disease itself.

Scientific references

Adamo, L., Rocha-Resende, C., Prabhu, S.D. et al. Reappraising the role of inflammation in heart failure. *Nat Rev Cardiol* 17, 269–285 (2020).

Frantz S, Falcao-Pires I, Balligand JL, et al. The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. *Eur J Heart Fail.* 2018;20(3):445-459. doi:10.1002/ejhf.1138

Jan K. Damås, Hans G. Eiken, Erik Øie, et al , Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure, *Cardiovascular Research*, Volume 47, Issue 4, September 2000, Pages 778–787, [https://doi.org/10.1016/S0008-6363\(00\)00142-5](https://doi.org/10.1016/S0008-6363(00)00142-5)

Type of contract

PhD scholarship of € 22.400 gross per year awarded by Humanitas University. This sum is exempt from IRPEF income tax according to the provisions of art. 4 of Law no. 476 of 13th August 1984, and is subject to social security contributions according to the provisions of art.



2, section 26 and subsequent sections, of Law no. 335 of 8th August 1995 and subsequent modifications.

Borsa di dottorato pari a € 22.400 annui lordi erogata da Humanitas University. Importo non soggetto a tassazione IRPEF a norma dell'art. 4 della L. 13 agosto 1984 n. 476 e soggetto, in materia previdenziale, alle norme di cui all'art. 2, commi 26 e segg., della L. 8 agosto 1995, n. 335 e successive modificazioni.